Nkarta, Inc.

Listed Company

NKTXCIK 0001787400NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-104.08M

Total Assets

$404.21M

Equity

$312.32M

Shares Out

71.29M

Op. Cash Flow

$-88.70M

Business

Nkarta, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. Its main product candidate is NKX019, a CD19-targeted CAR NK therapy being studied for multiple B‑cell mediated autoimmune diseases, and it also advances NKX101 and platform technologies for NK cell expansion, engineering, genome editing and cryopreservation. The company operates research and clinical development, proprietary manufacturing (cGMP) capabilities, and collaborative discovery programs. It conducts multi-center and investigator‑sponsored clinical trials in the United States and supplies frozen, on‑demand doses to clinical sites for administration.

Summary from filing dated 2025-03-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	90	97	97	91	63
General and administrative	32	31	35	28	23
Total operating expenses	122	128	132	119	86
Loss from operations	−122	−128	−132	−119	−86
Interest income	15	19	14	6	370,000
Other income, net	2	87,000	42,000	−470,000	−16,000
Total other income, net	18	19	14	5	354,000
Net loss	−104	−109	−118	−114	−86
Net unrealized (loss) gain on investments	−267,000	666,000	687,000	−529,000	—
Comprehensive loss	−104	−108	−117	−114	−86
Net loss per share, basic	−1.41	−1.6	−2.4	−2.61	−2.62
Net loss per share, diluted	−1.41	−1.6	−2.4	−2.61	−2.62
Weighted average shares outstanding used in computing net loss per share, basic	74	68	49	44	33
Weighted average shares outstanding used in computing net loss per share, diluted	74	68	49	44	33

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	40	28	31	37	61
Short-term investments	237	239	217	315	—
Prepaid expenses and other current assets	6	6	5	9	8
Total current assets	283	273	253	361	246
Long-term investments	16	110	—	—	—
Restricted cash	3	3	3	3	2
Property and equipment, net	67	75	79	62	13
Operating lease right-of-use assets	34	36	40	46	12
Other long-term assets	2	4	4	2	1
Total assets	404	501	379	473	274
Accounts payable	2	638,000	4	2	1
Operating lease liabilities, current portion	7	6	6	4	2
Accrued and other current liabilities	13	12	14	16	9
Total current liabilities	22	19	23	22	13
Operating lease liabilities, net of current portion	70	74	82	79	10
Other long-term liabilities	87,000	87,000	—	—	18,000
Total liabilities	92	93	106	101	23
Commitments and contingencies (Note 7)	—	—	—	—	—
Preferred stock, $0.0001 par value; 54,350,179 shares authorized; no shares issued and outstanding at December 31, 2025 and 2024	—	—	—	—	—
Common stock,$0.0001 par value; 200,000,000 shares authorized as of December 31, 2025 and 2024; 71,078,531 and 70,645,139 shares issued and outstanding at December 31, 2025 and 2024,respectively	7,000	7,000	5,000	5,000	3,000
Additional paid-in capital	960	952	709	691	455
Accumulated other comprehensive income	407,000	674,000	8,000	−679,000	−150,000
Accumulated deficit	−648	−544	−435	−318	−204
Total stockholders' equity	312	408	273	372	251
Total liabilities and stockholders' equity	404	501	379	473	274

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−104	−109	−118	−114	−86
Share-based compensation expense	9	17	17	17	14
Depreciation and amortization expense	9	9	6	3	2
Accretion of discount and amortization of premium on investments, net	−5	−7	−9	−818,000	3
Non-cash lease expense	2	2	2	4	367,000
Realized gain on investments	−94,000	—	−34,000	490,000	—
Impairment of right-of-use asset	791,000	0	4	—	—
Prepaid expenses and other assets	2	−1	2	−1	−4
Operating lease liabilities	−5	−6	5	32	—
Accounts payable and accrued and other liabilities	2	−4	4	3	3
Other long-term liabilities	—	87,000	—	—	—
Net cash used in operating activities	−89	−100	−86	−57	−68
Purchases of investments	−239	−406	−260	−386	—
Proceeds from maturities of investments	340	281	367	−248	—
Purchases of property and equipment	−1	−4	−28	−47	−5
Net cash provided by (used in) investing activities	100	−130	79	−185	33
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs	—	225	—	—	—
Proceeds from employee stock purchase plan purchases	141,000	343,000	530,000	445,000	—
Proceeds from stock option exercises	0	668,000	161,000	1	1
Net cash provided by financing activities	141,000	226	691,000	219	1
Net increase (decrease) in cash and cash equivalents	12	−3	−6	−23	−34
Acquisitions of property and equipment recorded in accounts payable and accrued and other current liabilities	390,000	343,000	268,000	5	—
Right-of-use assets recognized in exchange for operating lease liability	1	579,000	—	—	—
Decrease in right-of-use asset and lease liability due to termination	—	2	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro